Cargando…
Quantifying esophageal motion during free-breathing and breath-hold using fiducial markers in patients with early-stage esophageal cancer
INTRODUCTION: Cardiac toxicity after definitive chemoradiotherapy for esophageal cancer is a critical issue. To reduce irradiation doses to organs at risk, individual internal margins need to be identified and minimized. The purpose of this study was to quantify esophageal motion using fiducial make...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995399/ https://www.ncbi.nlm.nih.gov/pubmed/29889910 http://dx.doi.org/10.1371/journal.pone.0198844 |
_version_ | 1783330612450426880 |
---|---|
author | Doi, Yoshiko Murakami, Yuji Imano, Nobuki Takeuchi, Yuki Takahashi, Ippei Nishibuchi, Ikuno Kimura, Tomoki Nagata, Yasushi |
author_facet | Doi, Yoshiko Murakami, Yuji Imano, Nobuki Takeuchi, Yuki Takahashi, Ippei Nishibuchi, Ikuno Kimura, Tomoki Nagata, Yasushi |
author_sort | Doi, Yoshiko |
collection | PubMed |
description | INTRODUCTION: Cardiac toxicity after definitive chemoradiotherapy for esophageal cancer is a critical issue. To reduce irradiation doses to organs at risk, individual internal margins need to be identified and minimized. The purpose of this study was to quantify esophageal motion using fiducial makers based on four-dimensional computed tomography, and to evaluate the inter-CBCT session marker displacement using breath-hold. MATERIALS AND METHODS: Sixteen patients with early stage esophageal cancer, who received endoscopy-guided metallic marker placement for treatment planning, were included; there were 35 markers in total, with 9, 15, and 11 markers in the upper thoracic, middle thoracic, and lower thoracic/esophagogastric junction regions, respectively. We defined fiducial marker motion as motion of the centroidal point of the markers. Respiratory esophageal motion during free-breathing was defined as the amplitude of individual marker motion between the consecutive breathing and end-expiration phases, derived from four-dimensional computed tomography. The inter-CBCT session marker displacement using breath-hold was defined as the amplitudes of marker motion between the first and each cone beam computed tomography image. Marker motion was analyzed in the three regions (upper thoracic, middle thoracic, and lower thoracic/esophagogastric junction) and in three orthogonal directions (right-left; anterior-posterior; and superior-inferior). RESULTS: Respiratory esophageal motion during free-breathing resulted in median absolute maximum amplitudes (interquartile range), in right-left, anterior-posterior, and superior-inferior directions, of 1.7 (1.4) mm, 2.0 (1.5) mm, and 3.6 (4.1) mm, respectively, in the upper thoracic region, 0.8 (1.1) mm, 1.4 (1.2) mm, and 4.8 (3.6) mm, respectively, in the middle thoracic region, and 1.8 (0.8) mm, 1.9 (2.0) mm, and 8.0 (4.5) mm, respectively, in the lower thoracic/esophagogastric region. The inter-CBCT session marker displacement using breath-hold resulted in median absolute maximum amplitudes (interquartile range), in right-left, anterior–posterior, and superior-inferior directions, of 1.3 (1.0) mm, 1.1 (0.7) mm, and 3.3 (1.8) mm, respectively, in the upper thoracic region, 0.7 (0.7) mm, 1.1 (0.4) mm, and 3.4 (1.4) mm, respectively, in the middle thoracic region, and 2.0 (0.8) mm, 2.6 (2.2) mm, and 3.5 (1.8) mm, respectively, in the lower thoracic/esophagogastric region. CONCLUSIONS: During free-breathing, esophageal motion in the superior-inferior direction in all sites was large, compared to the other directions, and amplitudes showed substantial inter-individual variability. The breath-hold technique is feasible for minimizing esophageal displacement during radiotherapy in patients with esophageal cancer. |
format | Online Article Text |
id | pubmed-5995399 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-59953992018-06-21 Quantifying esophageal motion during free-breathing and breath-hold using fiducial markers in patients with early-stage esophageal cancer Doi, Yoshiko Murakami, Yuji Imano, Nobuki Takeuchi, Yuki Takahashi, Ippei Nishibuchi, Ikuno Kimura, Tomoki Nagata, Yasushi PLoS One Research Article INTRODUCTION: Cardiac toxicity after definitive chemoradiotherapy for esophageal cancer is a critical issue. To reduce irradiation doses to organs at risk, individual internal margins need to be identified and minimized. The purpose of this study was to quantify esophageal motion using fiducial makers based on four-dimensional computed tomography, and to evaluate the inter-CBCT session marker displacement using breath-hold. MATERIALS AND METHODS: Sixteen patients with early stage esophageal cancer, who received endoscopy-guided metallic marker placement for treatment planning, were included; there were 35 markers in total, with 9, 15, and 11 markers in the upper thoracic, middle thoracic, and lower thoracic/esophagogastric junction regions, respectively. We defined fiducial marker motion as motion of the centroidal point of the markers. Respiratory esophageal motion during free-breathing was defined as the amplitude of individual marker motion between the consecutive breathing and end-expiration phases, derived from four-dimensional computed tomography. The inter-CBCT session marker displacement using breath-hold was defined as the amplitudes of marker motion between the first and each cone beam computed tomography image. Marker motion was analyzed in the three regions (upper thoracic, middle thoracic, and lower thoracic/esophagogastric junction) and in three orthogonal directions (right-left; anterior-posterior; and superior-inferior). RESULTS: Respiratory esophageal motion during free-breathing resulted in median absolute maximum amplitudes (interquartile range), in right-left, anterior-posterior, and superior-inferior directions, of 1.7 (1.4) mm, 2.0 (1.5) mm, and 3.6 (4.1) mm, respectively, in the upper thoracic region, 0.8 (1.1) mm, 1.4 (1.2) mm, and 4.8 (3.6) mm, respectively, in the middle thoracic region, and 1.8 (0.8) mm, 1.9 (2.0) mm, and 8.0 (4.5) mm, respectively, in the lower thoracic/esophagogastric region. The inter-CBCT session marker displacement using breath-hold resulted in median absolute maximum amplitudes (interquartile range), in right-left, anterior–posterior, and superior-inferior directions, of 1.3 (1.0) mm, 1.1 (0.7) mm, and 3.3 (1.8) mm, respectively, in the upper thoracic region, 0.7 (0.7) mm, 1.1 (0.4) mm, and 3.4 (1.4) mm, respectively, in the middle thoracic region, and 2.0 (0.8) mm, 2.6 (2.2) mm, and 3.5 (1.8) mm, respectively, in the lower thoracic/esophagogastric region. CONCLUSIONS: During free-breathing, esophageal motion in the superior-inferior direction in all sites was large, compared to the other directions, and amplitudes showed substantial inter-individual variability. The breath-hold technique is feasible for minimizing esophageal displacement during radiotherapy in patients with esophageal cancer. Public Library of Science 2018-06-11 /pmc/articles/PMC5995399/ /pubmed/29889910 http://dx.doi.org/10.1371/journal.pone.0198844 Text en © 2018 Doi et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Doi, Yoshiko Murakami, Yuji Imano, Nobuki Takeuchi, Yuki Takahashi, Ippei Nishibuchi, Ikuno Kimura, Tomoki Nagata, Yasushi Quantifying esophageal motion during free-breathing and breath-hold using fiducial markers in patients with early-stage esophageal cancer |
title | Quantifying esophageal motion during free-breathing and breath-hold using fiducial markers in patients with early-stage esophageal cancer |
title_full | Quantifying esophageal motion during free-breathing and breath-hold using fiducial markers in patients with early-stage esophageal cancer |
title_fullStr | Quantifying esophageal motion during free-breathing and breath-hold using fiducial markers in patients with early-stage esophageal cancer |
title_full_unstemmed | Quantifying esophageal motion during free-breathing and breath-hold using fiducial markers in patients with early-stage esophageal cancer |
title_short | Quantifying esophageal motion during free-breathing and breath-hold using fiducial markers in patients with early-stage esophageal cancer |
title_sort | quantifying esophageal motion during free-breathing and breath-hold using fiducial markers in patients with early-stage esophageal cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995399/ https://www.ncbi.nlm.nih.gov/pubmed/29889910 http://dx.doi.org/10.1371/journal.pone.0198844 |
work_keys_str_mv | AT doiyoshiko quantifyingesophagealmotionduringfreebreathingandbreathholdusingfiducialmarkersinpatientswithearlystageesophagealcancer AT murakamiyuji quantifyingesophagealmotionduringfreebreathingandbreathholdusingfiducialmarkersinpatientswithearlystageesophagealcancer AT imanonobuki quantifyingesophagealmotionduringfreebreathingandbreathholdusingfiducialmarkersinpatientswithearlystageesophagealcancer AT takeuchiyuki quantifyingesophagealmotionduringfreebreathingandbreathholdusingfiducialmarkersinpatientswithearlystageesophagealcancer AT takahashiippei quantifyingesophagealmotionduringfreebreathingandbreathholdusingfiducialmarkersinpatientswithearlystageesophagealcancer AT nishibuchiikuno quantifyingesophagealmotionduringfreebreathingandbreathholdusingfiducialmarkersinpatientswithearlystageesophagealcancer AT kimuratomoki quantifyingesophagealmotionduringfreebreathingandbreathholdusingfiducialmarkersinpatientswithearlystageesophagealcancer AT nagatayasushi quantifyingesophagealmotionduringfreebreathingandbreathholdusingfiducialmarkersinpatientswithearlystageesophagealcancer |